Will PIONEER AF-PCI change my practice?

EuroIntervention 2017;13:e609-e612 published online e-edition August 2017. DOI: 10.4244/EIJV13I5A95

Christian Ukena
Christian Ukena1*, MD; Sergio Leonardi2, MD; Tullio Palmerini3, MD; Alexandra Lansky4, MD; Gilles Montalescot5, MD; Marco Valgimigli6, MD, PhD
1. Klinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; 2. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3. Dipartimento Cardiovascolare Policlinic

Introduction to the session: the trial headlines

The aim of the article is to capture the session at EuroPCR 2017 covering the PIONEER AF-PCI trial, communicate the analysis of the trialists, and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.

Gilles Montalescot as co-chair (with Marco Valgimigli) introduced the session. In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) on anticoagulation, additional dual antiplatelet therapy (DAPT) may reduce the risk for stent thrombosis and ischaemic events but increases the risk of bleeding. ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Coronary interventionsStable CADAdjunctive pharmacotherapy
Read next article
The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction

Latest news